Welcome to our dedicated page for REVIVA PHARMACEUTICALS HOLDINGS SEC filings (Ticker: RVPH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on REVIVA PHARMACEUTICALS HOLDINGS's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into REVIVA PHARMACEUTICALS HOLDINGS's regulatory disclosures and financial reporting.
Reviva Pharmaceuticals Holdings, Inc. has entered into agreements for a registered public offering raising aggregate gross proceeds of $10.0 million. The company will sell 6,283,334 shares of common stock and pre-funded warrants for up to 383,333 shares, together with Series G and Series H warrants exercisable for up to 6,666,667 shares each at an exercise price of $1.50 per share. Net proceeds are expected to be approximately $9.0 million, which Reviva plans to use, along with existing cash, to fund research and development, including its planned RECOVER-2 Phase 3 trial for brilaroxazine in schizophrenia, and for working capital and general corporate purposes. The warrants are immediately exercisable, with Series G expiring in five years and Series H in one year, and include beneficial ownership limits of 4.99% or 9.99%.
Reviva Pharmaceuticals Holdings, Inc. is offering 6,283,334 shares of common stock together with Series G and Series H common warrants and up to 383,333 Pre-Funded Warrants in a primary, best-efforts offering described in this prospectus supplement.
The combined public offering price is $1.50 per share and accompanying Series G and H Common Warrants; Series G warrants expire five years and Series H warrants expire 12 months after issuance. Pre-Funded Warrants carry a $0.0001 exercise price and may be used to avoid exceeding 4.99% (or, at purchaser election, 9.99%) beneficial ownership limits. The offering may terminate on April 13, 2026 and is expected to settle in a single closing; proceeds to the issuer are described as net of Placement Agent fees.
The prospectus supplement gives effect to a one-for-twenty reverse stock split effective March 9, 2026. Shares outstanding used to calculate post-offering figures are 6,443,710 as of March 17, 2026.
Reviva Pharmaceuticals Holdings, Inc. is offering shares of common stock together with Series G and Series H common warrants and pre-funded warrants in a public offering described in this preliminary prospectus supplement, subject to completion.
The offering is structured as bundled common stock (or pre-funded warrants) sold together with one Series G Common Warrant and one Series H Common Warrant per unit, with Series G exercisable for five years and Series H exercisable for 12 months. The company effected a one-for-twenty reverse stock split effective March 9, 2026. Shares outstanding were 6,443,710 as of March 16, 2026 (post-split). The offering is a best-efforts, no-minimum offering to be conducted at a fixed public offering price and expected to settle in a single closing. Use of proceeds is stated as funding R&D, including the planned RECOVER-2 Phase 3 trial for brilaroxazine, and for working capital and general corporate purposes.
Reviva Pharmaceuticals Holdings approved a one-for-twenty reverse stock split of its common stock, effective at 12:01 a.m. Eastern Time on March 9, 2026. Every 20 existing shares will convert into 1 share, with no fractional shares issued; holdings will be rounded up to the next whole share.
The par value and authorized share count will not change, but outstanding options and warrants will be adjusted for the new ratio. Reviva is using the reverse split as a key step to regain compliance with Nasdaq’s $1.00 minimum bid price requirement after receiving a delisting notice and a compliance extension through March 27, 2026.
The company warns that the reverse split announcement and implementation could pressure the stock price, reduce trading liquidity due to fewer outstanding shares, and that failure to meet Nasdaq’s listing standards could lead to delisting, harming liquidity, market value, and capital-raising ability.
683 Capital Management, 683 Capital Partners and Ari Zweiman filed Amendment No. 1 to a Schedule 13G updating their ownership in Reviva Pharmaceuticals Holdings, Inc. They may be deemed to beneficially own warrants to purchase 3,492,500 shares of common stock, all currently exercisable.
Based on 115,058,619 shares of common stock outstanding as of November 11, 2025, plus these warrant shares, their holdings represent about 3.0% of Reviva’s common stock. The filers state this amendment is an exit filing because they no longer own more than five percent and certify the securities are not held to change or influence control of the company.
Reviva Pharmaceuticals Holdings, Inc. reports that a Nasdaq Hearings Panel has granted the company an exception to regain compliance with Nasdaq’s $1.00 minimum bid price requirement for continued listing through March 27, 2026. This gives the company more time to bring its share price back above the required level.
The company adds a new risk factor explaining that it may implement a reverse stock split to help meet the bid price rule and that such a split could negatively affect its share price and trading liquidity. Reviva warns that failure to regain or maintain compliance with Nasdaq listing standards could lead to delisting, which could hurt the stock’s liquidity, price, and the company’s ability to raise capital or pursue business opportunities.
Reviva Pharmaceuticals Holdings, Inc. (RVPH) received an amended Schedule 13G filing showing that several Millennium-affiliated entities and Israel A. Englander collectively report beneficial ownership of Reviva common stock. The cover pages state that Integrated Core Strategies (US) LLC reports 3,254,631 shares, while Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander each report 3,257,670 shares of common stock, representing 2.8% of the outstanding class as of the event date of December 31, 2025. The filers indicate they own 5% or less of the company’s common stock and certify that the securities were not acquired and are not held for the purpose of changing or influencing control of Reviva.
Reviva Pharmaceuticals Holdings, Inc. (RVPH) furnished an 8-K announcing it issued a press release with financial information and operating metrics for the fiscal quarter ended September 30, 2025, and discussed its business outlook.
The materials were furnished under Items 2.02 and 7.01 and are not deemed “filed” for liability purposes. The press release is included as Exhibit 99.1.
Reviva Pharmaceuticals (RVPH) filed its Q3 2025 10‑Q, reporting a narrower net loss and added capital from recent offerings. Net loss was $4.0 million for the quarter (vs. $8.4 million a year ago) and $16.5 million for the nine months (vs. $23.7 million). Operating expenses declined sharply as R&D fell to $2.1 million and G&A to $1.9 million in Q3.
Cash and cash equivalents were $13.2 million with total assets of $14.3 million and current liabilities of $9.7 million. Stockholders’ equity improved to $4.5 million. The company completed a June 2025 offering (20.0M shares with Series C/D warrants; gross $10.0M, net about $9.0M) and a September 2025 offering (27.0M shares with Series E/F warrants; gross $9.0M, net about $8.1M). It also sold 2.45M shares via its ATM for roughly $1.2M net.
The company disclosed substantial doubt about its ability to continue as a going concern. Subsequent to quarter‑end, warrant exercises in October–November 2025 added 18.7M shares for approximately $6.4M gross. Shares outstanding were 96,337,119 as of September 30, 2025, and 115,058,619 as of November 11, 2025.